ES2194867T3 - Composiciones farmaceuticas para la administracion intranasal de apomorfina. - Google Patents

Composiciones farmaceuticas para la administracion intranasal de apomorfina.

Info

Publication number
ES2194867T3
ES2194867T3 ES94911944T ES94911944T ES2194867T3 ES 2194867 T3 ES2194867 T3 ES 2194867T3 ES 94911944 T ES94911944 T ES 94911944T ES 94911944 T ES94911944 T ES 94911944T ES 2194867 T3 ES2194867 T3 ES 2194867T3
Authority
ES
Spain
Prior art keywords
apomorphine
pharmaceutical compositions
intranasal administration
dihydroergotaminesalt
dihydroergotamine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94911944T
Other languages
English (en)
Inventor
Franciscus Wilhelmus He Merkus
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from BE9300298A external-priority patent/BE1006871A6/nl
Priority claimed from BE9300299A external-priority patent/BE1006872A6/nl
Priority claimed from BE9300297A external-priority patent/BE1006870A6/nl
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of ES2194867T3 publication Critical patent/ES2194867T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Abstract

LA INVENCION SE REFIERE A COMPOSICIONES FARMACEUTICAS PARA LA ADMINISTRACION INTRANASAL DE DIHIDROERGOTAMINA, APOMORFINA Y MORFINA QUE COMPRENDEN UNO DE ESTOS INGREDIENTES FARMACOLOGICAMENTE ACTIVOS EN COMBINACION CON CITODEXTRINA Y/O UN DISACARIDO, Y/O UN POLISACARIDO Y/O UN ALCOHOL DE AZUCAR.
ES94911944T 1993-03-26 1994-03-18 Composiciones farmaceuticas para la administracion intranasal de apomorfina. Expired - Lifetime ES2194867T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
BE9300298A BE1006871A6 (nl) 1993-03-26 1993-03-26 Nasale farmaceutische preparaten met apomorfine.
BE9300299A BE1006872A6 (nl) 1993-03-26 1993-03-26 Nasale farmaceutische preparaten met dihydroergotamine (dhe).
BE9300297A BE1006870A6 (nl) 1993-03-26 1993-03-26 Nasale farmaceutische preparaten met morfine.

Publications (1)

Publication Number Publication Date
ES2194867T3 true ES2194867T3 (es) 2003-12-01

Family

ID=27159799

Family Applications (2)

Application Number Title Priority Date Filing Date
ES98109002T Expired - Lifetime ES2239369T3 (es) 1993-03-26 1994-03-18 Composiciones farmaceuticas para administracion intranasal de dihidroergotamina.
ES94911944T Expired - Lifetime ES2194867T3 (es) 1993-03-26 1994-03-18 Composiciones farmaceuticas para la administracion intranasal de apomorfina.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES98109002T Expired - Lifetime ES2239369T3 (es) 1993-03-26 1994-03-18 Composiciones farmaceuticas para administracion intranasal de dihidroergotamina.

Country Status (10)

Country Link
US (2) US5756483A (es)
EP (2) EP0689438B1 (es)
JP (2) JPH08508472A (es)
AT (2) ATE241984T1 (es)
AU (1) AU6428894A (es)
DE (2) DE69432789T2 (es)
DK (2) DK0865789T3 (es)
ES (2) ES2239369T3 (es)
PT (2) PT689438E (es)
WO (1) WO1994022445A2 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199068I2 (de) * 1994-04-22 2004-05-06 Pentech Pharmaceuticals Inc Sublinguale Dosierungsformen enthaltend apomorphinzur Verwendung bei der Behandlung von erektiler D ysfunktion.
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US6395744B1 (en) 1994-04-22 2002-05-28 Queen's University At Kingston Method and compositions for the treatment or amelioration of female sexual dysfunction
US5612053A (en) 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
JPH11503750A (ja) * 1995-04-17 1999-03-30 サンチェズ，ロバート ウルシオールの錯体化
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
EP0834308A1 (en) * 1996-09-30 1998-04-08 LG Chemical Limited Ophthalmic formulation for treating myopia comprising dopamine agonist and cyclodextrin
US5855907A (en) * 1997-03-24 1999-01-05 Peyman; Gholam A. Method of treatment of migraine
US8631796B2 (en) 1997-04-10 2014-01-21 Cookgas, L.L.C. Laryngeal mask
EP1035833B1 (en) * 1997-12-02 2005-08-31 Archimedes Development Limited Compositions for nasal administration
PT1051155E (pt) * 1998-01-30 2002-10-31 Novartis Consumer Health Sa Solucoes nasais
US6403605B1 (en) 1998-05-29 2002-06-11 Queen's University At Kingston Methods for the normalization of sexual response and amelioration of long term genital tissue degradation
US20020002175A1 (en) * 2000-09-19 2002-01-03 Charanjit Behl Nasal delivery of apomorphine in combination with glycol derivatives
US6436950B1 (en) * 1998-08-14 2002-08-20 Nastech Pharmaceutical Company, Inc. Nasal delivery of apomorphine
CA2346656A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6225343B1 (en) 1999-06-16 2001-05-01 Nastech Pharmaceutical Company, Inc. Compositions and methods comprising morphine gluconate
ES2197792B1 (es) * 1999-06-16 2005-05-01 Nastech Pharmaceutical Co., Inc. Formulaciones farmaceuticas que contienen morfina intranasal.
GB9924797D0 (en) 1999-10-20 1999-12-22 West Pharm Serv Drug Res Ltd Compound
IL150034A0 (en) * 1999-12-30 2002-12-01 Tap Holdings Inc Oral mucosal dosage forms of apomorphine
BR0109515A (pt) 2000-04-07 2004-08-10 Tap Pharmaceutical Prod Inc Derivados da apomorfina e métodos para seu uso
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
DE10041478A1 (de) * 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
CA2429047A1 (en) 2000-11-15 2002-05-23 Tap Pharmaceutical Products, Inc. Treatment of anti-depression drug-induced sexual dysfunction with apomorphine
US20030027793A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal treatment of parkinson's disease
US20030026830A1 (en) * 2001-05-08 2003-02-06 Thomas Lauterback Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine
US20030017175A1 (en) * 2001-07-05 2003-01-23 R.T. Alamo Ventures I, Inc. Sublingual administration of dihydroergotamine for the treatment of migraine
US20030198669A1 (en) * 2001-07-05 2003-10-23 R.T. Alamo Ventures I, Llc Compositions and methods for rapid dissolving formulations of dihydroergotamine and caffeine for the treatment of migraine
US6685951B2 (en) 2001-07-05 2004-02-03 R. T. Alamo Ventures I, Inc. Administration of dihydroergotamine as a sublingual spray or aerosol for the treatment of migraine
US20030187011A1 (en) * 2001-12-20 2003-10-02 Lashuel Hilal A. Apomorphine inhibitors of amyloid-beta (Abeta) fibril formation and their use in amyloidosis based disease
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
BR0308567A (pt) * 2002-03-19 2007-01-09 Michael Holick derivados de glicosìdeo e glicosìdeo de ortoéster de apomorfina, análogos, e seus usos
EP1355158A1 (de) * 2002-04-19 2003-10-22 B.R.A.H.M.S Aktiengesellschaft Verfahren zur Diagnose von Entzündungserkrankungen und Infektionen unter Bestimmung des Phosphoproteins LASP-1 als Inflammationsmarker
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
US7736665B2 (en) * 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
JP4694207B2 (ja) 2002-07-05 2011-06-08 コルジウム ファーマシューティカル， インコーポレイテッド オピオイドおよび他の薬物に関する乱用抑止性の薬学的組成物
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
AU2003220808B2 (en) 2003-03-27 2008-08-21 Bioactis Limited Powder medicine applicator for nasal cavity
NZ542548A (en) 2003-03-31 2009-04-30 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
RU2364400C2 (ru) * 2003-04-14 2009-08-20 Вектура Лтд Фармацевтические композиции
US20040204439A1 (en) * 2003-04-14 2004-10-14 Staniforth John Nicholas Composition, device, and method for treating sexual dysfunction via inhalation
FR2857594B1 (fr) * 2003-07-17 2005-09-16 Servier Lab Composition pharmaceutique pour l'administration par voie nasale de piribedil
EP1663159A4 (en) * 2003-09-10 2010-06-09 Map Pharmaceuticals Inc AEROSOL FORMULATIONS FOR THE DELIVERY OF DIHYDROERGOTAMINE TO THE SYSTEMIC CIRCULATION BY PULMONARY INHALATION
US20050090518A1 (en) * 2003-10-24 2005-04-28 Nastech Pharmaceutical Company Inc. Method for treating parkinson's disease using apomorphine and apomorphine prodrugs
EP1547592A1 (en) * 2003-12-23 2005-06-29 Schwarz Pharma Ag Intranasal formulation of rotigotine
AU2004312096A1 (en) 2003-12-31 2005-07-21 Cydex Pharmaceuticals, Inc. Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
WO2005088655A1 (en) * 2004-03-12 2005-09-22 The Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin A magnetoresistive medium
CN101098678A (zh) * 2004-04-23 2008-01-02 锡德克斯公司 含有磺基烷基醚环糊精的dpi制剂
ES2653568T3 (es) 2004-06-12 2018-02-07 Collegium Pharmaceutical, Inc. Formulaciones de fármacos para la prevención del abuso
US8673360B2 (en) * 2004-08-10 2014-03-18 Shin Nippon Biomedical Laboratories, Ltd. Compositions that enable rapid-acting and highly absorptive intranasal administration
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
JP2009526860A (ja) * 2006-02-15 2009-07-23 ティカ レーケメデル アーベー 安定したコルチコステロイド混合物
GB2437488A (en) * 2006-04-25 2007-10-31 Optinose As Pharmaceutical oily formulation for nasal or buccal administration
ES2652415T3 (es) 2006-12-26 2018-02-02 Shin Nippon Biomedical Laboratories, Ltd. Preparación para aplicación transnasal
US20100111883A1 (en) * 2007-01-17 2010-05-06 Peter Vitins Cyclodextrin formulations
KR20090129998A (ko) 2007-02-11 2009-12-17 맵 파마슈티컬스, 인코포레이티드 부작용 프로파일을 최소화하면서 편두통의 빠른 완화를 가능하게 하는 ｄｈｅ의 치료적 투여 방법
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US20110111014A1 (en) * 2007-06-26 2011-05-12 Parkinson's Institute Methods and compositions for treatment of neurological disorders
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
WO2009040595A1 (en) * 2007-09-28 2009-04-02 Wockhardt Research Centre Multi-dose pharmaceutical composition of analgesic for nasal administration
GB0721394D0 (en) * 2007-10-31 2007-12-12 Vectura Group Plc Compositions for trating parkinson's disease
EP2057982A1 (en) 2007-11-09 2009-05-13 Archimedes Development Limited Intranasal compositions
US8040246B2 (en) * 2007-12-04 2011-10-18 Avaya Inc. Systems and methods for facilitating a first response mission at an incident scene
WO2010131486A1 (en) * 2009-05-15 2010-11-18 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) * 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
CA2784207C (en) * 2009-12-14 2018-06-05 Chiesi Farmaceutici S.P.A. Antibiotic microparticles for inhalation
TW201304822A (zh) 2010-11-15 2013-02-01 Vectura Ltd 組成物及用途
EP2545905A1 (en) * 2011-07-11 2013-01-16 Britannia Pharmaceuticals Limited A new therapeutical composition containing apomorphine as active ingredient
EP2877178A1 (en) 2012-07-26 2015-06-03 Wockhardt Limited Pharmaceutical composition comprising diamorphine for intranasal administration
CA2895816C (en) 2012-12-21 2021-02-23 Map Pharmaceuticals, Inc. 8'-hydroxy-dihydroergotamine compounds and compositions
DK3049059T3 (da) * 2013-09-24 2022-01-31 Satsuma Pharmaceuticals Inc Intranasal dhe formulering til behandlingen af hovedpine
IL257845B (en) 2015-09-10 2022-07-01 Impel Neuropharma Inc Lined nasal delivery device
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices
BR112020013744A8 (pt) * 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
GB2581431A (en) * 2018-12-11 2020-08-19 Satsuma Pharmaceuticals Inc Compositions, devices, and methods for treating or preventing headaches
CN113423400A (zh) 2018-12-11 2021-09-21 小蜜橘制药公司 用于治疗或预防头痛的组合物、装置和方法
US11786512B2 (en) 2019-09-23 2023-10-17 Slayback Pharma Llc Stable pharmaceutical compositions of dihydroergotamine mesylate
WO2022009248A1 (en) * 2020-07-07 2022-01-13 Jordan University Of Science And Technology A pharmaceutical composition for treating migraine headaches and a cosolvent method of preparation thereof
IT202100009857A1 (it) 2021-04-19 2022-10-19 Univ Degli Studi Di Torino Formulazione a rilascio controllato e prolungato di apomorfina
CN115804754A (zh) * 2022-12-16 2023-03-17 广州新济药业科技有限公司 吗啡鼻喷剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2750090A1 (de) * 1976-11-19 1978-06-01 Sandoz Ag Neue verabreichungsformen fuer organische verbindungen
US5169849A (en) * 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
DE3372705D1 (en) * 1982-04-30 1987-09-03 Takeda Chemical Industries Ltd Pharmaceutical composition and its use
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB8613688D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
SE8904295D0 (sv) * 1989-12-21 1989-12-21 Pharmacia Ab Smoking substitute
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
ATE112491T1 (de) * 1990-09-13 1994-10-15 Akzo Nobel Nv Stabilisierte feste chemische zusammensetzungen.
US5169840A (en) * 1991-03-27 1992-12-08 Nobipols Forskningsstiftelse Diequatorially bound β-1, 4 polyuronates and use of same for cytokine stimulation
GB9202464D0 (en) * 1992-02-05 1992-03-18 Danbiosyst Uk Composition for nasal administration
DE4207922A1 (de) * 1992-03-13 1993-09-23 Pharmatech Gmbh Wasserloesliche einschlussverbindungen und verfahren zu deren herstellung
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation

Also Published As

Publication number Publication date
PT865789E (pt) 2005-05-31
EP0865789B1 (en) 2005-03-16
WO1994022445A3 (en) 1995-01-05
DE69432789D1 (de) 2003-07-10
PT689438E (pt) 2003-10-31
US5942251A (en) 1999-08-24
DE69434304T2 (de) 2005-12-29
EP0689438A1 (en) 1996-01-03
ATE241984T1 (de) 2003-06-15
ATE290864T1 (de) 2005-04-15
AU6428894A (en) 1994-10-24
WO1994022445A2 (en) 1994-10-13
DE69432789T2 (de) 2003-12-04
DK0865789T3 (da) 2005-07-18
EP0689438B1 (en) 2003-06-04
EP0865789A3 (en) 1999-01-07
ES2239369T3 (es) 2005-09-16
DE69434304D1 (de) 2005-04-21
DK0689438T3 (da) 2003-09-29
US5756483A (en) 1998-05-26
JPH08508472A (ja) 1996-09-10
EP0865789A2 (en) 1998-09-23
JP2005041884A (ja) 2005-02-17

Similar Documents

Publication Publication Date Title
ES2194867T3 (es) Composiciones farmaceuticas para la administracion intranasal de apomorfina.
AU6463490A (en) Aerosol composition for topical medicament
AU1590995A (en) Novel carbamate derivative and medicinal composition containing the same
AU1218892A (en) Pharmaceutical aerosol formulations
NO944526D0 (no) Medisinsk aerosolformulering
AU8183691A (en) Pharmaceutical or cosmetic composition containing a combination of a retinoid and a sterol
MX9202839A (es) 4-aminoquinolinas y composiciones farmaceuticas de las mismas.
BR9606674B1 (pt) novo derivado de composto de antraciclina e preparação farmacêutica contendo o mesmo.
WO1997004788A3 (en) Use of calendula glycosides for the treatment of psoriasis
AU1306997A (en) Pharmaceutical compositions with vitamin d analogues
AU6624896A (en) Pharmaceutical composition
AU1282395A (en) Novel benzamide derivative and medicinal composition containing the same
AU4609693A (en) An interferon-alpha/beta binding protein its preparation and pharmaceutical compositions containing it
DE68908414T2 (de) Pharmazeutische zusammensetzungen für die reizung eines immunostimulierenden effektes.
ATE201996T1 (de) Hirudin enthaltende pharmazeutische zusammensetzungen
AU3361695A (en) Novel gnrh analogues with antitumour effects and pharmaceutical compositions thereof
ATE211383T1 (de) Topische aciclovir-zubereitung
ATE145824T1 (de) Aerosolformulierung enthaltend fusafungin
EP0219716A3 (en) Immunosuppressive agent
AU7318994A (en) Thf-gamma2 analogs and pharmaceutical compositions comprising them
ATA112689A (de) Feuchtigkeitswaechter, insbesondere fuer windeln u. dgl.
AU5908790A (en) Topical pharmaceutical compositions
AU5822090A (en) Humidity buffer formulation
EP1108716A3 (en) C7 taxane derivatives and pharmaceutical compositions containing them
ITMI931174A0 (it) Composizioni farmaceutiche per la cura della talassemia